

Annex 1

Updated (October 2022) COVID-19 AESI including status of associated Brighton case definitions

TABLE 1. Updated (October 2022) COVID-19 AESI including status of associated Brighton case definitions

AESI	Brighton Case Definition Status
Acute respiratory distress syndrome	Published
Multisystem inflammatory syndrome (children & adults) ^{3,4}	Published
<ul style="list-style-type: none"> Myocarditis / pericarditis Other forms of acute cardiac injury including arrhythmias, heart failure, coronary artery disease, myocardial infarction, stress cardiomyopathy 	<ul style="list-style-type: none"> Published No Brighton case definition to be developed but companion guide to myocarditis/pericarditis includes background rates and ICD/MedDRA codes
Thrombosis and Thromboembolism ^{3,4}	Published
Hemorrhagic disorders including DIC	Not yet started
<ul style="list-style-type: none"> Anosmia³ Ageusia^{3,4} 	<ul style="list-style-type: none"> To be submitted to Vaccine by Oct 31, 2022 No case definition to be developed
Chilblain – like lesions	Not yet started
Erythema multiforme ^{3,4}	Not yet started
Single Organ Cutaneous Vasculitis	Published
Acute kidney injury ^{3,4}	Published lab-based criteria (see *)
Acute liver injury	Published lab-based criteria (see #)
Acute pancreatitis ^{3,4}	Not yet started
Rhabdomyolysis	Not yet started
Subacute thyroiditis ^{3,4}	Not yet started
Anaphylaxis ^{1,2}	Published
Thrombocytopenia ^{1,2,3,4}	Published
Generalized convulsion ^{1,2}	Published
Acute disseminated encephalomyelitis ⁴	Published
Guillain Barré Syndrome ^{3,4}	Published
Acute aseptic arthritis ^{r-VSV}	Published
Aseptic meningitis ^{Live vaccines}	Published
Encephalitis / Encephalomyelitis ^{Live vaccines}	Published
Bell's Palsy ^{Intranasal EColi Heat Labile Toxin Adjuvanted Vaccine}	Published
Vaccine associated enhanced disease ^{1(Formalin inactivated measles/RSV; HIV), 2(Chimeric YF Dengue), 5 (SARS / MERS-CoVs)}	Published
Thrombocytopenia and Thrombosis Syndrome⁶	Proposed case definition posted online; Working group to be formed by end of 2022
Immune Thrombocytopenia (ITP)⁶	Thrombocytopenia published; revision needed
Capillary Leak Syndrome⁶ (Flare up in individuals with prior history of capillary leak syndrome)	Not yet started
Delayed hypersensitivity reaction⁶	Not yet started
Extensive limb swelling⁶	Not yet started

Facial swelling in individuals with dermal fillers ⁶	Not yet started
Dizziness and tinnitus ⁶	Not yet started

¹ Proven association with immunization encompassing several different vaccines

² Proven association with vaccine that could theoretically be true for novel COVID-19 vaccines

³ Theoretical concern based on wild type disease immunopathogenesis

⁴ Theoretical concern related to viral replication during wild type disease

⁵ Theoretical concern because it has been demonstrated in an animal model with ≥ 1 vaccine platform

⁶ Signal recognized and validated during COVID-19 mass campaigns or regulator(s) required update to product information

* Acute kidney injury—consensus definition of Kidney Disease Improving Global Outcomes expert consensus group www.kdigo.org

- Increase in serum creatinine by ≥ 0.3 mg/dl (≥ 26 μ mol/l) within 48 hours; OR
- Increase in serum creatinine to ≥ 1.5 times baseline, known or presumed to have occurred within prior 7 days OR
- Urine volume ≤ 0.5 ml/ kg/ hour for 6 hours

Acute liver injury – definition as used in majority of COVID-19 publications (but no international consensus):

- > 3-fold elevation above the upper normal limit for ALT or AST OR
- > 2-fold elevation above the upper normal limit for total serum bilirubin or GGT or ALP

• Case Definition and resources available at:

https://docs.google.com/spreadsheets/d/1QgF35nYcsaFN3DZT0tV_IP0TYqQzsDMUQBAd5M9brrM/edit#gid=1666959512